<qa>  What is the name of the biomarker used to examine the response and mechanisms of resistance toIV. To examine pre-treatment and serial biomarkers associated with response and mechanisms of resistance to venetoclax, obinutuzumab and ibrutinib when given in combination for relapsedrefractory or previously untreated patients with CLL. 